クロフィブラート

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H318：重篤な眼の損傷

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

クロフィブラート 価格

MSDS Information

• Ethyl 2-(4-chlorophenoxy)-2-methylpropionate

クロフィブラート 化学特性,用途語,生産方法

• 外観

  無色～わずかにうすい黄色, 澄明の液体

• 溶解性

  エタノール、アセトン及びジエチルエーテルに極めて溶けやすく、水にほとんど溶けない。

• 解説

  2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester．C12H15ClO3(242.71)．p-クロロフェノール，アセトン，水酸化ナトリウムをクロロホルム中で加熱還流後，得られたp-クロロフェノキシイソ酪酸をエチルエステル化すると得られる．"無色～淡黄色の液体．沸点150 ℃(2.66 kPa)．"1.137～1.144．"1.500～1.505．水に不溶，有機溶媒に易溶．コレステロール生合成経路を阻害し，血中コレステロールを減少させる．高脂血症治療薬として使用される．LD50 1.95 g/kg(ラット，経口)．[CAS 637-07-0]
  森北出版「化学辞典（第2版）

• 用途

  脂質の過酸化物の生理作用の研究。

• 医薬用

  クロフィブラートは，抗高脂血症（脂質異常症）剤で、血中のコレステロールを低下させる。無色ないし淡黄色の澄明な油状の液体で、特異なにおいがあり、味は初め苦くのちに甘い。カプセル剤として用いられる。作用機序としては、コレステロールの合成を阻害し、中性脂肪を低下させ、尿酸の排泄(はいせつ)を促進させる作用を有する。1日0.75～1.5グラムを2～3回に分けて内服する。［幸保文治］

• 効能

  脂質異常症治療薬, トリグリセリド合成阻害薬, ペルオキシソーム増殖因子活性化受容体(PPAR)α作動薬

• 商品名

  クロフィブラート (鶴原製薬)

• 確認試験

  (１) 本品のエタノール(99.5)溶液(1→10000)につき，紫外 可視吸光度測定法〈2.24〉により吸収スペクトルを測定し， 本品のスペクトルと本品の参照スペクトル1又はクロフィブ ラート標準品について同様に操作して得られたスペクトルを 比較するとき，両者のスペクトルは同一波長のところに同様 の強度の吸収を認める．また，本品のエタノール(99.5)溶液 (1→100000)につき，紫外可視吸光度測定法〈2.24〉により吸 収スペクトルを測定し，本品のスペクトルと本品の参照スペ クトル2又はクロフィブラート標準品について同様に操作し て得られたスペクトルを比較するとき，両者のスペクトルは 同一波長のところに同様の強度の吸収を認める．
  (２) 本品につき，赤外吸収スペクトル測定法〈2.25〉の液 膜法により試験を行い，本品のスペクトルと本品の参照スペ クトル又はクロフィブラート標準品のスペクトルを比較するとき，両者のスペクトルは同一波数のところに同様の強度の 吸収を認める．

• 定量法

  本品約0.5gを精密に量り，0.1mol/L水酸化カリウム・ エタノール液50mLを正確に加え，二酸化炭素吸収管(ソー ダ石灰)を付けた還流冷却器を用いて水浴中でしばしば振り 混ぜながら2時間加熱する．冷後，直ちに過量の水酸化カリ ウムを0.1mol/L塩酸で滴定〈2.50〉する(指示薬：フェノール フタレイン試液3滴)．同様の方法で空試験を行う．
  0.1mol/L水酸化カリウム・エタノール液1mL ＝24.27mg C₁₂H₁₅ClO₃

• 純度試験

  (１) 酸 本品2.0gを中和エタノール100mLに溶かし，フ ェノールフタレイン試液1滴及び0.1mol/L水酸化ナトリウム 液0.20mLを加えるとき，液の色は赤色である．
  (２) 重金属〈1.07〉 本品2.0gをとり，第2法により操作し， 試験を行う．比較液には鉛標準液2.0mLを加える(10ppm以 下)．
  (３) ヒ素〈1.11〉 本品5.0gに硝酸20mL及び硫酸5mLを加 え，白煙が発するまで加熱する．必要ならば，冷後，更に硝 酸5mLを加え，白煙が発生するまで加熱し，この操作を液 が無色～淡黄色となるまで繰り返す．冷後，シュウ酸アンモ ニウム飽和溶液15mLを加え，再び白煙が発生するまで加熱 し，冷後，水を加
  えて25mLとする．この液5mLを検液とし， 試験を行う． 標準色：本品を用いないで同様に操作して調製した液 5mLを発生瓶にとり，ヒ素標準液2.0mLを加え，以下 検液の試験と同様に操作する(2ppm以下)．
  (４) 4－クロロフェノール 本品1.0gをとり，内標準溶液 1mLを正確に加え，更に移動相を加えて5mLとし，試料溶 液とする．別に4－クロロフェノール10mgをとり，ヘキサ ン／2－プロパノール混液(9：1)に溶かし，正確に100mLと する．この液10mLを正確に量り，ヘキサン／2－プロパノ ール混液(9：1)を加えて正確に50mLとする．この液6mLを 正確に量り，内標準溶液4mLを正確に加え，更に移動相を 加えて20mLとし，標準溶液とする．試料溶液及び標準溶液 20μLにつき，次の条件で液体クロマトグラフィー〈2.01〉に より試験を行う．それぞれの液の内標準物質のピーク面積に 対する4－クロロフェノールのピーク面積の比Q T及びQ Sを 求めるとき，Q TはQ Sより大きくない．
  内標準溶液 4－エトキシフェノールの移動相溶液(1→ 30000)
  操作条件
  検出器：紫外吸光光度計(測定波長：275nm)
  カラム：内径約4mm，長さ約30cmのステンレス管に5 ～10μmの液体クロマトグラフィー用シアノプロピル シリル化シリカゲルを充てんする．
  カラム温度：25℃付近の一定温度
  移動相：ヘキサン／2－プロパノール／酢酸(100)混液 (1970：30：1)
  流量：クロフィブラートの保持時間が約2分になるよう に調整する．
  カラムの選定：本品10.0g，4－クロロフェノール6mg 及び4－エトキシフェノール6mgをヘキサン1000mL に溶かす．この液20μLにつき，上記の条件で操作す るとき，クロフィブラート，4－クロロフェノール， 4－エトキシフェノールの順に溶出し，クロフィブラ ートと4－クロロフェノールの分離度が5以上及び4－ クロロフェノールと4－エトキシフェノールの分離度 が2.0以上のものを用いる．

• 貯法

  保存条件 遮光して保存する．
  容器 気密容器．

• 強熱残分

  0.1％以下(1g)．

• 使用上の注意

  光によって徐々に分解する

• 説明

  Researchers in France observed in 1953 that structures derived from dehydrocholic acid, phenylethyl acetic acid, and certain other disubstituted acetic acids exhibited hypocholesterolemic properties in rats and humans. Several years later, Thorp and Waring discovered clof ibrate as an effective compound for lowering lipids in animal models, with minimal toxicity. Its mode of action was initially attributed to seasonal variations in adrenal and thyroid function, and the administration of androsterone was found to potentiate the hypocholesterolemic effect of this compound. Subsequently, several clinical trials were performed which showed that clofibrate decreases lipid levels in hypercholesterolemic patients, mainly as the result of a reduction in the very-low-density lipoprotein (VLDL), and less in the low-density lipoprotein (LDL) fraction, and that the coadministration of androsterone was not necessary for its hypolipidemic effect. Despite reported hepatomegaly in rats following long-term treatment with clofibrate, this drug was approved in the United States in 1967 for the treatment of hyperlipidemias.
  Clofibrate can be chemically synthesized by the condensation of phenol with ethyl 2-chloro-2-methylpropionate in the presence of a dehydrochlorinating agent, followed by chlorination and purification. It can also be synthesized by the condensation of p-chlorophenol with acetone and chloroform followed by esterifying the resultant acid to give clofibrate.

• 化学的特性

  Clear Colorless Oil

• 使用

  Clofibrate is a lipid-lowering agent (antilipidemic) used for controlling high cholesterol (anticholesteremic) and triacylglyceride levels in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, thereby reducing VLDL levels. It is indicated only in subjects with increased concentrations of VLDL and intermediate-density lipoproteins (IDL) who have failed to respond adequately to gemfibrozil or nicotinic acid. Clofibrate is of limited utility for patients with either familial hypercholesterolemia or polygenic hypercholesterolemia, as comparatively more effective drugs are available for lowering the concentration of LDL in these patients.
  Clofibrate has no effect on hyperchylomicronemia, nor does it affect concentrations of high-density lipoproteins (HDL). Thus, clofibrate appears to have specific efficacy only in patients with familial type-III hyperlipoproteinemia. There is no substantial evidence proving efficacy of clofibrate in preventing deaths from coronary artery disease. Clofibrate has been used to prevent or control polydipsia, polyuria, and dehydration in a limited number of patients with mild to moderate neurohypophyseal diabetes insipidus. A 5-year multicenter study reported failure of clofibrate in reducing or preventing mortality in cardiovascular disorders, which has provided a setback for the prophylactic use of this drug.

• 定義

  ChEBI: The ethyl ester of clofibric acid.

• 世界保健機関（WHO）

  Clofibrate, an antihyperlipidaemic agent, was introduced in 1967 and was subsequently extensively studied in the primary and secondary prevention of ischaemic heart disease. Following reports, published in 1978, of increased mortality among patients receiving clofibrate in a WHO-sponsored cooperative trial concerned with the primary prevention of ischaemic heart disease, the drug was withdrawn in some countries and its approved indications were severely restricted in many others. These restrictions have become the norm for more recently developed analogues of clofibrate. (Reference: (WHODI) WHO Drug Information, 2, 6, 1979)

• 一般的な説明

  Clofibrate, ethyl 2-(p-chlorophenoxy)-2-methylpropionate (Atromid-S), is a stable, colorless topale yellow liquid with a faint odor and a characteristictaste. It is soluble in organic solvents but insoluble in water.
  Clofibrate is prepared by a Williamson synthesis, condensingp-chlorophenol with ethyl -bromoisobutyrate, or bythe interaction of a mixture of acetone, p-chlorophenol, andchloroform in the presence of excess potassium hydroxide.The acid obtained by either of these methods is esterified togive clofibrate. Both acid and ester are active; the latter, however,is preferred for medicinal use. Clofibrate is hydrolyzedrapidly to 2-p-chlorophenoxy-2-methylpropionic acid by esterasesin vivo and, bound to serum albumin, circulates inblood. The acid has been investigated as a hypolipidemicagent. It is absorbed more slowly and to a smaller extent thanis the ester. The aluminum salt of the acid gives even lowerblood levels than p-chlorophenoxy-2-methylpropionic acid.

• 危険性

  Questionable carcinogen; toxic; causes nausea, vomiting, diarrhea, weakness, stiffness, cramps, and muscle tenderness.

• 生物活性

  PPAR agonist (EC 50 values are 50, 500 and > 100 μ M at PPAR α , PPAR γ and PPAR δ respectively). Antihyperlipoproteinemic.

• 作用機序

  The three structurally related fibrates available in the United States are gemfibrozil (Lopid), fenofibrate (Tricor) and clofibrate (Atromid-S).They share common uses and toxicities. The fibrates typically lower VLDL triglyceride by 40% or more and elevate plasma HDL cholesterol by 10 to 15%. The reduction of plasma triglycerides in humans appears due to increased lipoprotein lipase (LPL) activity. The fibrates activate a nuclear receptor (transcription factor) termed peroxisomal proliferation activated receptor (PPAR) that is a member of the steroid hormone receptor superfamily. PPAR increases transcription of the LPL gene and decreases transcription of the apolipoprotein CIII gene (apo CIII). Since LPL is responsible for catabolism of VLDL triglyceride and apo CIII is an inhibitor of LPL activity, the combined consequences of these changes are increased LPL activity and enhanced removal of triglyceride from the circulation.
  The elevation of HDL levels by fibrates may be due to two drug actions: induced synthesis of apo-A1, the principal apoprotein of HDL, and increased assembly of new HDL particles in the circulation. Surface components of VLDL contribute to formation of HDL, as the VLDL particles are reduced in size through the action of LPL.The increased rate of catabolism of VLDL caused by the fibrates would provide more components for assembly of HDL particles.

• 臨床応用

  Clofibrate is the drug of choice in the treatment of typeIII hyperlipoproteinemias and may also be useful, to a lesserextent, in types IIb and IV hyperlipoproteinemias. The drugis not effective in types I and IIa.
  Clofibrate can lower plasma concentrations of both triglyceridesand cholesterol, but it has a more consistent clinicaleffect on triglycerides. It also affects lipoprotein plasmalevels by enhancing removal of triglycerides from the circulationand causes reduction of VLDL by stimulatinglipoprotein lipase to increase the catabolism of this lipoproteinto LDL. Clofibrate lowers triglyceride levels in theserum much more than cholesterol levels and decreases levelsof FFAs and phospholipids. The lowering of cholesterollevels may result from more than one mechanism. Clofibrateinhibits the incorporation of acetate into the synthesis ofcholesterol, between the acetate and mevalonate step, by inhibitingsn-glyceryl-3-phosphate acyltransferase. Clofibratealso regulates cholesterol synthesis in the liver by inhibitingmicrosomal reduction of 3-hydroxy-3-methylglutaryl-CoA(HMG-CoA), catalyzed by HMG-CoA reductase. Clofibratemay lower plasma lipids by means other than impairment ofcholesterol biosynthesis, such as increasing excretionthrough the biliary tract.

• 副作用

  The fibrates are generally well tolerated, with GI distress being the most likely complaint. Other adverse effects include myositis and erectile dysfunction, particularly with clofibrate. There is ongoing concern about the fibrates increasing the risk of gallstones, although the extent of risk is unclear. Because clofibrate was associated with increased mortality in early clinical trials, it should be considered as a second-line drug.

• 安全性プロファイル

  Poison by intravenous route.Moderately toxic by ingestion and other routes. Anexperimental teratogen. Other experimental reproductiveeffects. Reduces plasma lipid levels. Human systemiceffects by ingestion: muscle weakness, muscle spasms, andfever. Q

• 薬物相互作用

  The fibrates potentiate the actions of the coumarin anticoagulants, such as warfarin, so care should be taken to reduce the dose of simultaneously administered anticoagulants, and plasma prothrombin should be frequently measured until the level stabilizes. As mentioned earlier, great care should be given to combining a statin with a fibrate, since this combination may increase the risk of myositis and perhaps rhabdomyolysis.

• 環境運命予測

  Clofibrate characteristically reduces plasma triglycerides by lowering the concentration of VLDL within 2–5 days after initiation of therapy. In a majority of patients, total cholesterol and LDL concentrations in plasma fall slightly. However, some patients who exhibit a large fall in VLDL may show a paradoxical rise in LDL, resulting in minimal net effect on total cholesterol levels.
  The drug has several proposed antilipidemic actions, including increased triglyceride and VLDL clearance, mobilization of cholesterol from tissues, increased fecal excretion of neutral sterols, decreased hepatic lipoprotein synthesis and/or secretion, decreased free fatty acid release, and decreased triglyceride synthesis. The precise mechanisms by which clofibrate lowers serum concentrations of triglycerides and cholesterol are not known.

• 代謝

  The pro-drug fenofibrate undergoes rapid hydrolysis to produce fenofibric acid. This active metabolite can then be further metabolized by oxidative or conjugative pathways. Gemfibrozil is slightly different in that it does not require initial bioactivation; however, similar to fenofibric acid, it can be oxidized or conjugated. Oxidation of the aromatic methyl groups produces inactive hydroxymethyl and carboxylic acid analogues. As a drug class, fibrates and their oxidized analogues are primarily excreted as glucuronide conjugates in the urine. Oxidization requires the CYP3A4 isozyme; however, because of the ability of these compounds to be conjugated and eliminated either with or without oxidation, drug interactions with other compounds affecting the CYP3A4 system are less important here than with other drug classes.

クロフィブラート 上流と下流の製品情報

クロフィブラート 生産企業

Global(258)Suppliers

クロフィブラート スペクトルデータ(¹HNMR、IR1、MS、Raman)

637-07-0, クロフィブラート キーワード